Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683395 · ClinicalTrials.gov registry record · Phase 1
A Study of PLX51107 in Advanced Malignancies
A Phase 1 study, sponsored by Plexxikon.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02683395 is a Phase 1 study that was terminated before completion, run by Plexxikon. The registered enrollment target is 50 participants.
The verdict
NCT02683395, a Phase 1 study, was terminated before completion, sponsored by Plexxikon.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies
Interventions
- DRUG PLX51107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683395
The ClinicalTrials.gov registry entry for NCT02683395 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Plexxikon, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PLX51107 is the first listed.
NCT02683395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683395 about?
NCT02683395 is a clinical study titled "A Study of PLX51107 in Advanced Malignancies". The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies
What is the current status of trial NCT02683395?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2016-03. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02683395?
The interventions under investigation include: PLX51107 (DRUG).
Who is sponsoring clinical trial NCT02683395?
This trial is sponsored by Plexxikon, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.